SDS

Across TCGA pan-cancer cohorts, SDS Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SDS data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher SDS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SDS expression acts as an unfavorable survival marker.

LGG, LIHC, and SARC are the cancer types where SDS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.240	0.830	<.001	12	view →
LIHC	OS	Median	All	0.031	0.777	<.001	12	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.617	0.886	.029	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SDS–LGG (OS)

Open the LGG breakdown →